The SIMSA Act of 2024 establishes a new "Schedule A" category in the Controlled Substances Act specifically to address drug analogues that are imported or offered for import into the United States. Under this new schedule, the Attorney General can quickly identify and regulate synthetic drugs with chemical structures and effects similar to existing controlled substances, closing what supporters view as a legal loophole that allows illicit drug producers to create slightly modified versions of banned drugs. The bill allows the Attorney General to temporarily schedule substances for up to five years while gathering evidence, then permanently schedule them if warranted, though the Secretary of Health and Human Services can block permanent scheduling if scientific evidence shows the substance lacks sufficient abuse potential. Penalties for importing or distributing Schedule A substances are severe, including up to 20 years imprisonment for first offenses and up to 30 years for those with prior drug convictions, with enhanced fines up to $5 million for individuals and $10 million for organizations. The legislation also requires clear labeling of Schedule A substances using international chemical nomenclature and establishes registration requirements for legitimate research, analytical, or industrial uses, while protecting ongoing research activities by allowing researchers to continue their work during the temporary scheduling period.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.